NASDAQ:TSHA Taysha Gene Therapies Q1 2025 Earnings Report $2.46 -0.12 (-4.46%) As of 01:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Taysha Gene Therapies EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/ATaysha Gene Therapies Revenue ResultsActual RevenueN/AExpected Revenue$1.48 millionBeat/MissN/AYoY Revenue GrowthN/ATaysha Gene Therapies Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Taysha Gene Therapies Earnings HeadlinesTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from BrokeragesMay 5 at 3:29 AM | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2 at 8:00 AM | globenewswire.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 5, 2025 | Brownstone Research (Ad)Taysha Gene Therapies (NASDAQ:TSHA) Receives "Market Outperform" Rating from JMP SecuritiesApril 29, 2025 | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 29, 2025 | americanbankingnews.comTaysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited OpportunityApril 16, 2025 | seekingalpha.comSee More Taysha Gene Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Taysha Gene Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your email. Email Address About Taysha Gene TherapiesTaysha Gene Therapies (NASDAQ:TSHA), a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.View Taysha Gene Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Upcoming Earnings American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025)Brookfield Asset Management (5/6/2025)Duke Energy (5/6/2025)Energy Transfer (5/6/2025)Mplx (5/6/2025)Ferrari (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
